The closed loop therapy study will trial the world’s most advanced commercial automated insulin delivery system (MiniMed™ 780G) in youth with broad ethnic backgrounds. The study will identify if AHCL is an appropriate and safe therapy for youth struggling with diabetes. While better control of glucose levels is a key outcome for this trial, other features such as burden reduction, improved quality of life and treatment satisfaction will also be explored.
This world-first longitudinal study will be an important step towards integrating AHCL technology into regular diabetes care for youth, with the expectation that it will reduce daily diabetes management burden and improve short-term and long-term health outcomes in this high risk group.
For more information, contact Associate Professor Ben Wheeler.
New technology, like the intermittently scanned continuous glucose monitoring (isCGM; FreeSyle® Libre 2) could improve glucose monitoring and diabetes control for children, as it discreetly provides accurate and up-to-date glucose information.
The Flash-2 study aims to investigate the isCGM device using a randomised controlled trial in 100 young NZ children (aged 4-13 years). Given children’s propensity for new technology, the ease of being able to scan (even through clothing), and the reduction in finger pricking, isCGM may provide a great opportunity to engage children in their diabetes care and help them and their families to improve self-management behaviours.
This study continues the research group’s broad aim of helping to provide healthier, more equitable and cost-effective diabetes care to children and their families.
To find out if your child is eligible for this study please contact Associate Professor Ben Wheeler.